Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Novonesis (Novozymes) B

Ylin-
Alin-
Vaihto-
2026 Q3 - tulosraportti
12 päivää sitten
2,35 DKK/osake
Viimeisin osinko
1,44%Tuotto/v

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMäärä
186
3
411
2 431
693

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
11.2.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
5.11.
2026 Q2 - tulosraportti
20.8.
2026 Q1 - tulosraportti
5.5.
2025 Q4 - tulosraportti
25.2.
2025 Q3 - tulosraportti
6.11.2025

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
  • Käyttäjän profiilikuva
    11.11. · Muokattu
    ·
    There is a price potential of a full 30 % if the analysts are right......So hold on to your shares - we are going much higher up....... Novonesis target price raised after interim report 6 Nov. 07:46 ∙ News overview (AI) The Danish biotech company Novonesis (Novozymes) B experienced an increase in the share price following the publication of the company's latest interim report. In response to the financial results, a number of leading financial institutions have upgraded their target prices for the company. These widespread adjustments reflect strong analyst confidence, and several prominent banks reiterate positive recommendations such as 'Buy' or 'Overweight'. Novonesis (Novozymes) B shares rose 3 % on Nasdaq Copenhagen following the publication of the company's interim report. SEB and Nordea set the highest new target prices at respectively 580 DKK (up from 560 DKK) and 575 DKK (up from 540 DKK), and both maintain the 'Buy' recommendation. Barclays raised its target price to 510 DKK (from 500 DKK) with an 'Overweight' recommendation, while Danske Bank raised its target price to 465 DKK (from 455 DKK) with a 'Hold' recommendation. BNP Paribas raised its target price to 455 DKK (from 420 DKK) and maintains a 'Neutral' recommendation.
    Käyttäjän profiilikuva
    14 t sitten
    ·
    Testing the price 410, then I will accumulate.
  • Käyttäjän profiilikuva
    10.11.
    Unfortunate slump the last week. Was hoping that this would be a beneficiary of potential AI sector rotation
    Käyttäjän profiilikuva
    11.11.
    ·
    It will probably come back up, but it is a bit calmer than average, though it is way down now. However, it is a biotech stock whose potential for development is quite large with many branches out as well as acquisitions of small fry.
  • Käyttäjän profiilikuva
    10.11.
    ·
    Givaudan has delivered a reasonable return this year, both on share price and exchange rate. The price relation to Novonesis is interesting today. Rarely has the relative price of Novonesis been this low. Have therefore shifted Givaudan to Novonesis.
  • Käyttäjän profiilikuva
    6.11.
    ·
    Geopolitics is making customers seek other solutions, says Novonesis CFO Close today at 10:01 ∙ MarketWire Novonesis (Novozymes) B 4,51% Sky-high oil prices due to geopolitical unrest are causing many countries to seek alternative energy sources. And Novonesis plays a role here, as the group supplies enzymes used to make bioethanol. "We have not seen the big picture change in relation to our Bioenergy division. The activity level has increased - especially in emerging markets," says Novonesis CFO Rainer Lehmann to MarketWire. Here, the CFO specifically points to Asian countries, highlighting India, Indonesia, and Vietnam as drivers. Looking at total revenue in Asia Pacific in July, August, and September, it rose to 206.5 million euros compared to 193.4 million euros in the 2025 quarter. Emerging markets overall accounted for revenue of 437.3 million euros, up from 404.2 million euros in the third quarter of last year. DOUBLE-DIGIT GROWTH RATES IN ENERGY In the financial report, Novonesis writes that the energy division alone "was driven by double-digit growth in energy across most regions, reflecting increased production and adoption of solutions for ethanol and biodiesel." "We see that energy security is a theme. That people are pursuing sources other than oil. We have seen, among other things, that the blending ratio in fuel is shifting in many countries," says Rainer Lehmann. It is a matter of how much bioethanol is blended into regular fuel. For example, looking at the US, the sale of gasoline with a higher bioethanol content, E15, has been opened for the entire year this year. And Novonesis, which sells enzymes to American farmers for precisely ethanol production, is in the race to get farmers to choose the Danish company's enzymes for production. The proposal for permanent permission for nationwide year-round sales is to be voted on after the midterm elections. According to Haider Anjum, senior analyst at Jyske Bank, a potential expansion of E15 in the US is not yet factored into the group's long-term plans. He points out that it will be additional upside for sales. .\˙ MarketWire
  • Käyttäjän profiilikuva
    5.11.
    Good earnings as expected
    Käyttäjän profiilikuva
    5.11.
    ·
    Yes, so the share price is probably going down today ;-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Välittäjätilasto

Dataa ei löytynyt
2026 Q3 - tulosraportti
12 päivää sitten
2,35 DKK/osake
Viimeisin osinko
1,44%Tuotto/v

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
  • Käyttäjän profiilikuva
    11.11. · Muokattu
    ·
    There is a price potential of a full 30 % if the analysts are right......So hold on to your shares - we are going much higher up....... Novonesis target price raised after interim report 6 Nov. 07:46 ∙ News overview (AI) The Danish biotech company Novonesis (Novozymes) B experienced an increase in the share price following the publication of the company's latest interim report. In response to the financial results, a number of leading financial institutions have upgraded their target prices for the company. These widespread adjustments reflect strong analyst confidence, and several prominent banks reiterate positive recommendations such as 'Buy' or 'Overweight'. Novonesis (Novozymes) B shares rose 3 % on Nasdaq Copenhagen following the publication of the company's interim report. SEB and Nordea set the highest new target prices at respectively 580 DKK (up from 560 DKK) and 575 DKK (up from 540 DKK), and both maintain the 'Buy' recommendation. Barclays raised its target price to 510 DKK (from 500 DKK) with an 'Overweight' recommendation, while Danske Bank raised its target price to 465 DKK (from 455 DKK) with a 'Hold' recommendation. BNP Paribas raised its target price to 455 DKK (from 420 DKK) and maintains a 'Neutral' recommendation.
    Käyttäjän profiilikuva
    14 t sitten
    ·
    Testing the price 410, then I will accumulate.
  • Käyttäjän profiilikuva
    10.11.
    Unfortunate slump the last week. Was hoping that this would be a beneficiary of potential AI sector rotation
    Käyttäjän profiilikuva
    11.11.
    ·
    It will probably come back up, but it is a bit calmer than average, though it is way down now. However, it is a biotech stock whose potential for development is quite large with many branches out as well as acquisitions of small fry.
  • Käyttäjän profiilikuva
    10.11.
    ·
    Givaudan has delivered a reasonable return this year, both on share price and exchange rate. The price relation to Novonesis is interesting today. Rarely has the relative price of Novonesis been this low. Have therefore shifted Givaudan to Novonesis.
  • Käyttäjän profiilikuva
    6.11.
    ·
    Geopolitics is making customers seek other solutions, says Novonesis CFO Close today at 10:01 ∙ MarketWire Novonesis (Novozymes) B 4,51% Sky-high oil prices due to geopolitical unrest are causing many countries to seek alternative energy sources. And Novonesis plays a role here, as the group supplies enzymes used to make bioethanol. "We have not seen the big picture change in relation to our Bioenergy division. The activity level has increased - especially in emerging markets," says Novonesis CFO Rainer Lehmann to MarketWire. Here, the CFO specifically points to Asian countries, highlighting India, Indonesia, and Vietnam as drivers. Looking at total revenue in Asia Pacific in July, August, and September, it rose to 206.5 million euros compared to 193.4 million euros in the 2025 quarter. Emerging markets overall accounted for revenue of 437.3 million euros, up from 404.2 million euros in the third quarter of last year. DOUBLE-DIGIT GROWTH RATES IN ENERGY In the financial report, Novonesis writes that the energy division alone "was driven by double-digit growth in energy across most regions, reflecting increased production and adoption of solutions for ethanol and biodiesel." "We see that energy security is a theme. That people are pursuing sources other than oil. We have seen, among other things, that the blending ratio in fuel is shifting in many countries," says Rainer Lehmann. It is a matter of how much bioethanol is blended into regular fuel. For example, looking at the US, the sale of gasoline with a higher bioethanol content, E15, has been opened for the entire year this year. And Novonesis, which sells enzymes to American farmers for precisely ethanol production, is in the race to get farmers to choose the Danish company's enzymes for production. The proposal for permanent permission for nationwide year-round sales is to be voted on after the midterm elections. According to Haider Anjum, senior analyst at Jyske Bank, a potential expansion of E15 in the US is not yet factored into the group's long-term plans. He points out that it will be additional upside for sales. .\˙ MarketWire
  • Käyttäjän profiilikuva
    5.11.
    Good earnings as expected
    Käyttäjän profiilikuva
    5.11.
    ·
    Yes, so the share price is probably going down today ;-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMäärä
186
3
411
2 431
693

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
11.2.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
5.11.
2026 Q2 - tulosraportti
20.8.
2026 Q1 - tulosraportti
5.5.
2025 Q4 - tulosraportti
25.2.
2025 Q3 - tulosraportti
6.11.2025

Välittäjätilasto

Dataa ei löytynyt
2026 Q3 - tulosraportti
12 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
11.2.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
5.11.
2026 Q2 - tulosraportti
20.8.
2026 Q1 - tulosraportti
5.5.
2025 Q4 - tulosraportti
25.2.
2025 Q3 - tulosraportti
6.11.2025
2,35 DKK/osake
Viimeisin osinko
1,44%Tuotto/v

Foorumi

Liity keskusteluun Nordnet Socialissa
  • Käyttäjän profiilikuva
    11.11. · Muokattu
    ·
    There is a price potential of a full 30 % if the analysts are right......So hold on to your shares - we are going much higher up....... Novonesis target price raised after interim report 6 Nov. 07:46 ∙ News overview (AI) The Danish biotech company Novonesis (Novozymes) B experienced an increase in the share price following the publication of the company's latest interim report. In response to the financial results, a number of leading financial institutions have upgraded their target prices for the company. These widespread adjustments reflect strong analyst confidence, and several prominent banks reiterate positive recommendations such as 'Buy' or 'Overweight'. Novonesis (Novozymes) B shares rose 3 % on Nasdaq Copenhagen following the publication of the company's interim report. SEB and Nordea set the highest new target prices at respectively 580 DKK (up from 560 DKK) and 575 DKK (up from 540 DKK), and both maintain the 'Buy' recommendation. Barclays raised its target price to 510 DKK (from 500 DKK) with an 'Overweight' recommendation, while Danske Bank raised its target price to 465 DKK (from 455 DKK) with a 'Hold' recommendation. BNP Paribas raised its target price to 455 DKK (from 420 DKK) and maintains a 'Neutral' recommendation.
    Käyttäjän profiilikuva
    14 t sitten
    ·
    Testing the price 410, then I will accumulate.
  • Käyttäjän profiilikuva
    10.11.
    Unfortunate slump the last week. Was hoping that this would be a beneficiary of potential AI sector rotation
    Käyttäjän profiilikuva
    11.11.
    ·
    It will probably come back up, but it is a bit calmer than average, though it is way down now. However, it is a biotech stock whose potential for development is quite large with many branches out as well as acquisitions of small fry.
  • Käyttäjän profiilikuva
    10.11.
    ·
    Givaudan has delivered a reasonable return this year, both on share price and exchange rate. The price relation to Novonesis is interesting today. Rarely has the relative price of Novonesis been this low. Have therefore shifted Givaudan to Novonesis.
  • Käyttäjän profiilikuva
    6.11.
    ·
    Geopolitics is making customers seek other solutions, says Novonesis CFO Close today at 10:01 ∙ MarketWire Novonesis (Novozymes) B 4,51% Sky-high oil prices due to geopolitical unrest are causing many countries to seek alternative energy sources. And Novonesis plays a role here, as the group supplies enzymes used to make bioethanol. "We have not seen the big picture change in relation to our Bioenergy division. The activity level has increased - especially in emerging markets," says Novonesis CFO Rainer Lehmann to MarketWire. Here, the CFO specifically points to Asian countries, highlighting India, Indonesia, and Vietnam as drivers. Looking at total revenue in Asia Pacific in July, August, and September, it rose to 206.5 million euros compared to 193.4 million euros in the 2025 quarter. Emerging markets overall accounted for revenue of 437.3 million euros, up from 404.2 million euros in the third quarter of last year. DOUBLE-DIGIT GROWTH RATES IN ENERGY In the financial report, Novonesis writes that the energy division alone "was driven by double-digit growth in energy across most regions, reflecting increased production and adoption of solutions for ethanol and biodiesel." "We see that energy security is a theme. That people are pursuing sources other than oil. We have seen, among other things, that the blending ratio in fuel is shifting in many countries," says Rainer Lehmann. It is a matter of how much bioethanol is blended into regular fuel. For example, looking at the US, the sale of gasoline with a higher bioethanol content, E15, has been opened for the entire year this year. And Novonesis, which sells enzymes to American farmers for precisely ethanol production, is in the race to get farmers to choose the Danish company's enzymes for production. The proposal for permanent permission for nationwide year-round sales is to be voted on after the midterm elections. According to Haider Anjum, senior analyst at Jyske Bank, a potential expansion of E15 in the US is not yet factored into the group's long-term plans. He points out that it will be additional upside for sales. .\˙ MarketWire
  • Käyttäjän profiilikuva
    5.11.
    Good earnings as expected
    Käyttäjän profiilikuva
    5.11.
    ·
    Yes, so the share price is probably going down today ;-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMäärä
186
3
411
2 431
693

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki